HAOHAI BIOTEC(06826): Intraocular cross-linked sodium hyaluronate gel products obtained medical device registration certificate.
Hao Hai Biotechnology (06826) announced that its wholly-owned subsidiary, Shanghai Qisheng Biopharmaceutical Co., Ltd. (hereinafter referred to as "Qisheng Biopharm"), recently received the "Medical Device Registration Certificate of the People's Republic of China" issued by the National Medical Products Administration for the intraocular use cross-linked hyaluronic acid sodium gel product (hereinafter referred to as "the product").
HAOHAI BIOTEC (06826) announced that its wholly-owned subsidiary, Shanghai Qi Sheng Biotech Co., Ltd. ("Qi Sheng Biotech"), recently received the "Medical Device Registration Certificate of the People's Republic of China" issued by the National Medical Products Administration for the intraocular use cross-linked sodium hyaluronate gel product (referred to as "this product").
Related Articles
Shanghai Laimu Electronics (603633.SH) actual controller Fang Peijiao plans to reduce their stake by no more than 3%.
NET263 Ltd. (002467.SZ) major shareholder Lee Xiaolong plans to reduce his shareholding by no more than 2%.
YIDU TECH (02158) spent approximately 11.2844 million Hong Kong dollars to repurchase 1.9088 million shares on March 16th.
Shanghai Laimu Electronics (603633.SH) actual controller Fang Peijiao plans to reduce their stake by no more than 3%.
NET263 Ltd. (002467.SZ) major shareholder Lee Xiaolong plans to reduce his shareholding by no more than 2%.
YIDU TECH (02158) spent approximately 11.2844 million Hong Kong dollars to repurchase 1.9088 million shares on March 16th.
